Q3 2022 Earnings Estimate for GoodRx Holdings, Inc. Issued By SVB Leerink (NASDAQ:GDRX)

GoodRx Holdings, Inc. (NASDAQ:GDRXGet Rating) – Equities researchers at SVB Leerink lowered their Q3 2022 EPS estimates for GoodRx in a report issued on Monday, August 1st. SVB Leerink analyst S. Davis now expects that the company will post earnings of $0.02 per share for the quarter, down from their prior estimate of $0.03. SVB Leerink currently has a “Market Perform” rating and a $10.00 price objective on the stock. The consensus estimate for GoodRx’s current full-year earnings is $0.03 per share. SVB Leerink also issued estimates for GoodRx’s FY2022 earnings at $0.07 EPS, FY2023 earnings at $0.26 EPS and FY2024 earnings at $0.44 EPS.

GoodRx (NASDAQ:GDRXGet Rating) last announced its quarterly earnings results on Monday, May 9th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.01. GoodRx had a negative net margin of 1.86% and a positive return on equity of 2.86%. The company had revenue of $203.30 million for the quarter, compared to analysts’ expectations of $200.61 million. During the same quarter in the previous year, the company earned ($0.01) earnings per share. GoodRx’s quarterly revenue was up 26.7% on a year-over-year basis.

Several other research firms have also commented on GDRX. Cowen dropped their price objective on shares of GoodRx from $22.00 to $9.00 in a research note on Monday, June 13th. Royal Bank of Canada reissued a “sector perform” rating and set a $6.50 price objective (down previously from $8.00) on shares of GoodRx in a research note on Thursday, June 23rd. Cowen dropped their price objective on shares of GoodRx from $22.00 to $9.00 and set a “market perform” rating on the stock in a research note on Monday, June 13th. Bank of America assumed coverage on shares of GoodRx in a research note on Monday, June 6th. They set a “buy” rating and a $11.00 price objective on the stock. Finally, Barclays dropped their price objective on shares of GoodRx from $15.00 to $12.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 20th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $16.39.

GoodRx Price Performance

Shares of NASDAQ GDRX opened at $6.50 on Wednesday. GoodRx has a 1 year low of $5.61 and a 1 year high of $48.05. The company has a debt-to-equity ratio of 0.83, a current ratio of 16.76 and a quick ratio of 16.76. The company’s 50-day moving average is $6.66 and its 200 day moving average is $14.49. The stock has a market capitalization of $2.58 billion, a P/E ratio of -162.50, a P/E/G ratio of 14.22 and a beta of 0.77.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AdvisorNet Financial Inc increased its holdings in GoodRx by 275.0% during the first quarter. AdvisorNet Financial Inc now owns 1,875 shares of the company’s stock valued at $36,000 after buying an additional 1,375 shares during the last quarter. CWM LLC increased its holdings in GoodRx by 50.2% during the first quarter. CWM LLC now owns 2,224 shares of the company’s stock valued at $43,000 after buying an additional 743 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in GoodRx during the second quarter valued at approximately $59,000. SG Americas Securities LLC purchased a new stake in GoodRx during the second quarter valued at approximately $63,000. Finally, Whittier Trust Co. purchased a new stake in GoodRx during the second quarter valued at approximately $75,000. Institutional investors own 52.60% of the company’s stock.

GoodRx Company Profile

(Get Rating)

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

Read More

Earnings History and Estimates for GoodRx (NASDAQ:GDRX)

Want More Great Investing Ideas?

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.